July 25, 2023 07:33 AM EDT
People

Bio­gen ex­pects to re­duce head­count by 1,000 un­der $700M op­er­a­tional sav­ings plan 

Kyle LaHucik

Senior Reporter

Fresh off two FDA green lights — a full ap­proval for Alzheimer’s and an ac­cel­er­at­ed nod in ALS — Bio­gen CEO Chris Viehbach­er is bring­ing down the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Au­toim­mune CAR-T da­ta dump: Kyver­na, Ca­balet­ta shares fall af­ter un­veil­ing ear­ly-stage re­sults

Ex­clu­sive: For­mer Mer­ck sci­en­tists raise $85M to map and drug pro­tein in­ter­ac­tions in can­cer and au­toim­mune dis­ease

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Stephen Squin­to talks writ­ing checks and next-gen obe­si­ty drugs as JP Mor­gan clos­es first $500M+ biotech fund

Gilead can­cer drug ma­grolimab showed wor­ry­ing trends around death

sponsored

De-risk­ing the pa­tient jour­ney in cell ther­a­pies: Six key con­sid­er­a­tions

A service from the Financial Times